Migraine Market Update: CGRP Inhibitors Slowly Gain Ground
New Medicines For The Condition More Than Doubled This Year
The market for novel preventive and acute treatments grew from three anti-CGRP antibodies at the start of 2020 to four biologics and two oral drugs against CGRP plus a small molecule 5-HT1F inhibitor.
